drugset / Trial / NCT00794131

Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors

NCT00794131

Phase 1 Completed 43 enrolled Genelux GmbH
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to determine whether, GL-ONC1, an Oncolytic Virus, can safely be administered intravenously in patients with advanced solid tumors.

Timeline

Start
2008-11
Primary completion
2015-11
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Olvimulogene nanivacirepvec Other / unclassified Intravenous